Here are the 10-K annual reports from Wellgistics Health, Inc. (WGRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow WGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGRX filings page.
Wellgistics Health, Inc. filed Amendment No. 1 to its annual report to update governance and ownership information. The amendment restates the sections on directors, executive officers and beneficial ownership and adds exhibits, including the company’s compensation recovery (clawback) policy.
The filing details a refreshed leadership team, including President Prashant Patel, Interim Chief Financial Officer Eric Sherb, and Chairman Suren Ajjarapu, along with three independent directors. It also describes the audit and nominating/compensation committees and confirms that Gary Herman is the audit committee financial expert.
The amendment provides a detailed beneficial ownership table as of March 2, 2026, showing significant holdings by insiders and one additional holder over 5%. It also summarizes the company’s code of ethics and insider trading policy, including blackout periods and a prohibition on short sales by employees, officers and directors.
Wellgistics Health, Inc. files its annual report describing a fast‑growing healthcare ecosystem built around specialty‑lite pharmaceuticals, wholesale distribution and a digital pharmacy hub. The company operates through Wellgistics Pharmacy, wholesale unit Wellgistics LLC, technology platform DelivMeds and holding entity Wood Sage.
Wellgistics closed the Wellgistics LLC acquisition on August 30, 2024, with consideration including a $10 million closing cash payment, a $15 million promissory note and equity‑based bonuses, later restructured into 3,999,335 restricted shares. The cash payment is now due the earlier of 120 days after its Form S‑1 becomes effective or August 30, 2025. The report highlights its 5P‑Model serving patients, providers, pharmacies, payors and manufacturers, and lists extensive risk factors around integration, reimbursement pressure, competition, regulation, debt and technology reliance.